Keyword: ARCH Venture Partners
The new funding will propel Unity Biotechnologies' osteoarthritis asset into its first clinical trial.
The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells used to break proteins apart.
Ex-Receptos CEO Faheem Hasnain has been keeping a low profile since selling the company to Celgene, but now he is back at the helm of a new biotech.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
The round positions Semma to start learning whether its insulin-producing cells can control blood sugar levels in Type 1 diabetics.
The series C, which moves Codiak’s total haul up toward $170 million, tees the biotech up to move its lead candidate into clinical trials.
Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.
KSQ has interrogated 20,000 human genes across 600 cancer- and immune-based models, providing it with a wealth of data to power drug discovery.
After announcing this year’s Fierce 15 winners, we invited their executives to the Drug Development Forum in Boston to discuss some of the pivotal moments leading up to their win.